# Xellar Raises $50 Million Series A Financing to Build the Future of 3D Bio Intelligence

- Link: https://www.thailand-business-news.com/pr-news/xellar-raises-50-million-series-a-financing-to-build-the-future-of-3d-bio-intelligence
- Published: 2026-06-30T09:06:00+07:00
- Author: PR Newswire

**Financing will accelerate the development of human-relevant biological data infrastructure,
virtual cell technologies, and next-generation drug discovery**

BOSTON, June 30, 2026 /PRNewswire/ — Xellar Biosystems today announced the closing
of $50 million in Series A and A+ financing to advance its vision of building the
world’s leading 3D Bio Intelligence platform. The financing will support the expansion
of Xellar’s integrated technology stack spanning organ-on-chip systems, laboratory
automation, high-content imaging, multi-omics analysis, and AI-driven biological
modeling.

Drug discovery remains one of the most challenging and resource-intensive endeavors
in modern science. Despite remarkable advances in artificial intelligence, the industry
continues to face a fundamental bottleneck: the lack of scalable, human-relevant
biological data. Xellar was founded on the belief that the future of drug discovery
will be built upon a new generation of biological infrastructure capable of generating,
understanding, and ultimately predicting human biology.

At the core of Xellar’s platform is a closed-loop system that combines human organ-
on-chip models, automated experimentation, and computational intelligence. By continuously
generating high-quality, multi-dimensional biological data under physiologically
relevant conditions, Xellar is creating the foundation for a new class of biological
foundation models and virtual cell systems.

Unlike traditional preclinical approaches that rely heavily on animal models or 
simplified in vitro assays, Xellar captures biological processes in dynamic, high-
dimensional space, enabling deeper insights into mechanism of action, toxicity, 
disease progression, and therapeutic response. This combination of human-relevant
biology and machine intelligence allows researchers to move beyond observation toward
prediction.

"AI alone will not revolutionize drug discovery," said Xin Xie, PhD, Founder and
CEO of Xellar. "The future belongs to organizations that can generate high-quality
human data at scale. We believe organ-on-chip systems, automation, and AI must work
together in a closed-loop flywheel. Our mission is to transform biology from something
we observe into something we can systematically understand, model, and ultimately
predict."

With this financing, Xellar will further expand its automated biological data generation
capabilities, strengthen its AI and computational biology teams, and accelerate 
the development of virtual cell technologies that bridge experimental biology and
computational modeling.

By combining human-relevant biological systems with machine intelligence, Xellar
aims to redefine how medicines are discovered and developed, enabling a future where
biological innovation becomes faster, more predictive, and fundamentally more scalable.

About Xellar

Xellar Biosystems is an AI-driven biotech company using Organ-on-a-Chip (OoC) technology,
advanced imaging, and machine learning to accelerate drug discovery and development
by creating realistic 3D human tissue models for testing drugs, assessing toxicity,
and predicting clinical outcomes more efficiently than traditional methods. Founded
in 2022, they combine wet-lab experiments with AI to analyze complex biological 
data, aiming to reduce costs, time, and improve the success rate of bringing new
therapies to market, serving the biopharmaceutical industry.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Xellar Raises $50 Million Series A Financing to Build the Future of 3D Bio Intelligence ](http://www.prnasia.com/story/archive/4995001_CN95001_0?rand=184833)